Literature DB >> 15996001

Dimethyl sulfone in human cerebrospinal fluid and blood plasma confirmed by one-dimensional (1)H and two-dimensional (1)H-(13)C NMR.

Udo F H Engelke1, Albert Tangerman, Michèl A A P Willemsen, Detlef Moskau, Sandra Loss, S Harvey Mudd, Ron A Wevers.   

Abstract

(1)H-NMR spectroscopy at 500 MHz was used to confirm that a previously unidentified singlet resonance at 3.14 ppm in the spectra of cerebrospinal fluid and plasma samples corresponds to dimethyl sulfone (DMSO(2)). A triple resonance inverse cryogenic NMR probe, with pre-amplifier and the RF-coils cooled to low temperature, was used to obtain an (1)H-(13)C HSQC spectrum of CSF containing 8 microM (753 ng/ml) DMSO(2). The (1)H-(13)C correlation signal for DMSO(2) was assigned by comparison with the spectrum from an authentic reference sample. In plasma and CSF from healthy controls, the concentration of DMSO(2) ranged between 0 and 25 micromol/l. The concentration of DMSO(2) in plasma from three of four patients with severe methionine adenosyltransferase I/III (MAT I/III) deficiency was about twice the maximum observed for controls. Thus, DMSO(2) occurs as a regular metabolite at low micromolar concentrations in cerebrospinal fluid and plasma. It derives from dietary sources, from intestinal bacterial metabolism and from human endogenous methanethiol metabolism. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996001     DOI: 10.1002/nbm.966

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  21 in total

1.  Tissue, urine and blood metabolite signatures of chronic kidney disease in the 5/6 nephrectomy rat model.

Authors:  Munsoor A Hanifa; Martin Skott; Raluca G Maltesen; Bodil S Rasmussen; Søren Nielsen; Jørgen Frøkiær; Troels Ring; Reinhard Wimmer
Journal:  Metabolomics       Date:  2019-08-17       Impact factor: 4.290

2.  Macrophage-Mediated Clofazimine Sequestration Is Accompanied by a Shift in Host Energy Metabolism.

Authors:  Julie Trexel; Gi S Yoon; Rahul K Keswani; Cora McHugh; Larisa Yeomans; Victor Vitvitsky; Ruma Banerjee; Sudha Sud; Yihan Sun; Gus R Rosania; Kathleen A Stringer
Journal:  J Pharm Sci       Date:  2016-12-20       Impact factor: 3.534

3.  Assessment of safety and efficacy of methylsulfonylmethane on bone and knee joints in osteoarthritis animal model.

Authors:  Junko Ezaki; Miyuki Hashimoto; Yu Hosokawa; Yoshiko Ishimi
Journal:  J Bone Miner Metab       Date:  2012-08-10       Impact factor: 2.626

4.  Analyses of volatile organic compounds from human skin.

Authors:  M Gallagher; C J Wysocki; J J Leyden; A I Spielman; X Sun; G Preti
Journal:  Br J Dermatol       Date:  2008-07-14       Impact factor: 9.302

5.  Methionine attenuates the intensity of rheumatoid arthritis by downregulating NF-κB and iNOS expression in neonatal rats.

Authors:  Shi Wang; Shenglan Tian; Mingzhe Li; Zhichao Li
Journal:  3 Biotech       Date:  2018-06-30       Impact factor: 2.406

6.  Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study.

Authors:  Eytan M Debbi; Gabriel Agar; Gil Fichman; Yaron Bar Ziv; Rami Kardosh; Nahum Halperin; Avi Elbaz; Yiftah Beer; Ronen Debi
Journal:  BMC Complement Altern Med       Date:  2011-06-27       Impact factor: 3.659

7.  Experimental and theoretical Electron Paramagnetic Resonance (EPR) study on the temperature-dependent structural changes of methylsulfanylmethane.

Authors:  Recep Tapramaz; Ercan Türkkan; Ömer Dereli
Journal:  Int J Mol Sci       Date:  2011-08-03       Impact factor: 5.923

8.  Methylsulfonylmethane suppresses breast cancer growth by down-regulating STAT3 and STAT5b pathways.

Authors:  Eun Joung Lim; Dae Young Hong; Jin Hee Park; Youn Hee Joung; Pramod Darvin; Sang Yoon Kim; Yoon Mi Na; Tae Sook Hwang; Sang-Kyu Ye; Eon-Soo Moon; Byung Wook Cho; Kyung Do Park; Hak Kyo Lee; Taekyu Park; Young Mok Yang
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

9.  Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.

Authors:  Henricus A M Mutsaers; Udo F H Engelke; Martijn J G Wilmer; Jack F M Wetzels; Ron A Wevers; Lambertus P van den Heuvel; Joost G Hoenderop; Rosalinde Masereeuw
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

10.  Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.

Authors:  Fanny Mochel; Perrine Charles; François Seguin; Julie Barritault; Christiane Coussieu; Laurence Perin; Yves Le Bouc; Christiane Gervais; Guislaine Carcelain; Anne Vassault; Josué Feingold; Daniel Rabier; Alexandra Durr
Journal:  PLoS One       Date:  2007-07-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.